Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Adicet Bio (Nasdaq: ACET) has granted inducement awards to two new employees hired in March 2025. The awards consist of non-qualified stock options to purchase 38,600 shares of Adicet's common stock at an exercise price of $0.76 per share, matching the closing price on March 31, 2025.

The vesting schedule includes 25% of shares vesting after one year, with the remaining 75% vesting in 36 monthly installments. Full vesting occurs on the fourth anniversary, contingent on continued employment. These awards were granted through Adicet's 2022 Inducement Plan, approved by the compensation committee as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025.

Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet’s common stock with an exercise price of $0.76 per share, the closing price of Adicet’s common stock as reported by Nasdaq on March 31, 2025. One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of each recipient’s start date and thereafter the remaining three-fourths of the shares underlying each employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient’s start date, in each case, subject to each such employee’s continued employment with Adicet on such vesting dates.

All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331844557/en/

Adicet Bio, Inc.

Investor and Media Contacts

Investors:

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Precision AQ

212-362-1200

janhavi.mohite@precisionaq.com

Media:

Kerry Beth Daly

kbdaly@adicetbio.com

Source: Adicet Bio, Inc.

FAQ

What inducement awards did Adicet Bio (ACET) grant in March 2025?

Adicet Bio granted stock options for 38,600 shares at $0.76 per share to two new employees, with a four-year vesting schedule.

What is the vesting schedule for Adicet Bio's (ACET) March 2025 stock options?

25% vests after one year, remaining 75% vests monthly over 36 months, completing in four years, subject to continued employment.

What was the exercise price for ACET's March 2025 inducement stock options?

The exercise price was $0.76 per share, matching Adicet's closing stock price on March 31, 2025.

Under what plan were ACET's March 2025 inducement awards granted?

The awards were granted under Adicet's 2022 Inducement Plan, outside of stockholder-approved equity incentive plans.